the Use of Magnesium Sulfate for Prevention of Postspinal Shivering

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

90 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-01-15

Study Completion Date

2020-06-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Shivering is an unpleasant experience after spinal anesthesia. Shivering is defined as an involuntary, repetitive activity of skeletal muscles. The mechanisms of shivering in patients undergoing surgery are mainly intraoperative heat loss, increased sympathetic tone, pain, and systemic release of pyrogens. Spinal anesthesia significantly impairs the thermoregulation system by inhibiting tonic vasoconstriction, which plays a significant role in temperature regulation. Spinal anesthesia also causes redistribution of core heat from the trunk (below the block level) to the peripheral tissues. These two effects predispose patients to hypothermia and shivering. The median incidence of shivering related to regional anesthesia observed in a review of 21 studies is 64.4%. Shivering increases oxygen consumption, lactic acidosis, carbon dioxide production, and metabolic rate by up to 400%. Therefore, shivering may cause problems in patients with low cardiac and pulmonary reserves. The best way to avoid these intraoperative and postoperative shivering-induced increases in hemodynamic and metabolic demands is to prevent shivering in the first place. Although magnesium is among several pharmacological agents used for the treatment of shivering, its effects on prevention of shivering during central neuraxial blockade have not been evaluated to date. Henceforth, the aim of this study was to evaluate the effect of magnesiume on shivering during spinal anesthesia.

Aim:

to compare the efficacy of intravenous versus intrathecal magnesium sulphate for prevention of post spinal shivering in adult patients undergoing elective lower limb orthopedic surgeries.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Adding Magnesium Sulphate in Pericapsular Nerve Group Block

NCT06180031

Hip Fractures

NOT_YET_RECRUITING PHASE2/PHASE3

Magnesium Sulphate in the Ultrasound-guided Supraclavicular Brachial Plexus Block

NCT02752334

Pain

COMPLETED PHASE2

Intravenous Versus Perineural Dexmedetomidine as Adjuvant in Adductor Canal Block for Total Knee Arthroplasty

NCT04266145

Post Spinal Anesthesia Shivering

COMPLETED NA

Postoperative Analgesia of Magnesium Sulfate in Suprascapular Nerve Block Following Shoulder Arthroscopy

NCT03602469

Arthroscopic Shoulder Surgery

UNKNOWN NA

Magnesium-sulfate as Adjuvant in Prehospital Femoral Nerve Block for Patient With Diaphysial Femoral Fracture.

NCT03597945

Acute Pain Due to Trauma

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prevention of Postspinal Shivering

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

The patients will be randomly allocated to Groups (\[T\], Intrathecal MgSo4 and \[M\], IV infusion MgSo4 groups) on the basis of computer-generated random numbers. Patients belonging to Group T (n = 45) will receive 50 mg intrathecal MgSo4 added to 0.5% hyperbaric bupivacaine \[131\],while those belonging to Group M (group, n = 45) will receive IV magnesium sulfate 50 mg/kg in 100 mL isotonic saline over 20 min as a bolus then 2 mg/kg/h infusion using a separate infusion set after administering spinal anesthesia.

Axillary temperature and grades of shivering will be noted every 10 min by the same anesthesiologist who performed the spinal anesthesia using Crossley and Mahajan scale,\[8\] If grade III, IV shivering persisted for \>10 min pethidine 25 mg IV will be administered as a rescue drug and number of patients required rescue drug will be recorded.

Primary Study Purpose

PREVENTION

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intrathecal Mg group

45 patients will receive 50 mg intrathecal MgSo4 added to 0.5% hyperbaric bupivacaine

Group Type EXPERIMENTAL

Magnesium Sulfate 1000 MG

Intervention Type DRUG

intrathecal versus IV infusion of Magnesium sulfate for prevention of postspinal shivering

IV Mg infusion group

45 patients will receive IV magnesium sulfate 50 mg/kg in 100 mL isotonic saline over 20 min as a bolus then 2 mg/kg/h infusion using a separate infusion set after administering spinal anesthesia

Group Type EXPERIMENTAL

Magnesium Sulfate 1000 MG

Intervention Type DRUG

intrathecal versus IV infusion of Magnesium sulfate for prevention of postspinal shivering

control

0.5% heavy bupivacaine in the spinal with no additives

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Magnesium Sulfate 1000 MG

intrathecal versus IV infusion of Magnesium sulfate for prevention of postspinal shivering

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age between 20-45 years old
* Both genders
* ASA I, II

Exclusion Criteria

* Patients with hemodynamic instability
* cardiopulmonary
* renal , liver disease
* hypo or hyperthyroidism
* cerebrovascular insufficiency
* coagulation defects
* those with psychiatric disorder
* patients receiving vasoactive drugs or beta blockers
* BMI \> 35
* allergic to study drug
* height \<160 cm or \>190 cm
* basal body temperature \>38°C or \<36°C
* those who received blood transfusion or \>2000 mL fluid intra-operatively
* surgery duration \> 3 hours

Minimum Eligible Age

20 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes